Stock · CAPLIPOINT · Healthcare
CAPLIPOINT share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for CAPLIN POINT LABORATORIES LIMITED, refreshed every end-of-day run. A systematic, data-only read on CAPLIN POINT LABORATORIES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads CAPLIPOINT as constructive with a Crack Score of 98/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readNear-perfect · scanned 21 Jul 2026
Where CAPLIPOINT stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
One directional side cleared its price-structure, filed-evidence and signed money-flow gates with no blocking red flag.
Technical axis
100/100Fundamental axis
100/100Money flow
75/100Result pulse · Q4 FY26
85/100Named setups in force
- stage2 uptrend
- pullback to rising MA
- under accumulation
- RS leader
- earnings acceleration
- quality margins
- relative value
- result winner
Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
uptrend frame (50 > 200 DMA)
50DMA rising
pulled back to a rising MA
orderly dip from highs
money-flow score 74.6/100
up/down volume 3.19x (buyers dominant)
MFI 58.2
net +6 accumulation days (25d)
relative strength rising vs NIFTY
RS line near its highs (leadership)
RS slope +50.3% (3m)
outperforming and above 50DMA
Fundamental evidence
net profit +19.0% YoY
revenue +19.45% YoY
net margin 28.81%
result score 85.0/100
net margin 28.81% (high)
result score 85.0/100
profit not shrinking YoY
revenue +19.45% YoY
cheaper than sector (0.61x median)
bottom-half P/E within sector
result score 85.0/100
earnings not shrinking
result score 85.0/100 (top tier)
strong filed quarter
profit up YoY
revenue up YoY
Valuation and context
P/E 30.9 vs sector median 50.4 (0.61x, 19th pctile)
P/E 1.62x its own ~15m median (19.1)
Relative valuation
P/E (TTM)
30.9P/E vs sector
+0.6%Sector percentile
19PEG
1.63Growth gap
-1.0%P/E vs own history
+1.6%The engine's trade frame
Entry zone
2,608.0Stop
2,470.2Target 1
2,883.6Target 2
3,021.4Risk / reward
5.3% risk · 2.0RScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for CAPLIPOINT are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the CAPLIPOINT chart, refreshed every end-of-day run.
The Crack Score, and how it is built98 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for CAPLIPOINT, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on CAPLIPOINT reads right now.
The editorial price read on CAPLIPOINT is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on CAPLIPOINT can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving CAPLIPOINT.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why CAPLIPOINT moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
CAPLIN POINT LABORATORIES LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
85 / 100Revenue
Rs 600 crNet profit
Rs 173 crEPS (quarter)
Rs 22.38| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +19.4% | +10.6% |
| Net profit | +19.0% | +4.2% |
| Net margin | +28.8% | |
Figures are the Q4 FY26 result for CAPLIN POINT LABORATORIES LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
CAPLIN POINT LABORATORIES LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
CAPLIPOINT official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 600 cr | Rs 22.38 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 543 cr | Rs 21.56 | n/a | 58/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 534 cr | Rs 20.32 | n/a | 58/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 510 cr | Rs 20.10 | n/a | 58/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 502 cr | Rs 18.75 | n/a | 58/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 493 cr | Rs 18.28 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 483 cr | Rs 17.22 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 459 cr | Rs 16.32 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 453 cr | Rs 16.01 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 436 cr | Rs 15.44 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 410 cr | Rs 15.13 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 395 cr | Rs 13.62 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 389 cr | Rs 13.45 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 372 cr | Rs 12.86 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 359 cr | Rs 12.09 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 346 cr | Rs 11.21 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 339 cr | Rs 10.43 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 326 cr | Rs 9.90 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 304 cr | Rs 9.91 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 300 cr | Rs 9.37 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 279 cr | Rs 8.78 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Standalone, audited | Rs 123 cr | Rs 5.48 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 268 cr | Rs 7.52 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Standalone, audited | Rs 1 cr | Rs 5.55 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Standalone, audited | Rs 100 cr | Rs 6.63 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 228 cr | Rs 7.74 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Standalone, audited | Rs 133 cr | Rs 5.26 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 193 cr | Rs 6.64 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 187 cr | Rs 6.58 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Standalone, audited | Rs 140 cr | Rs 4.88 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 156 cr | Rs 6.21 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Standalone, audited | Rs 125 cr | Rs 0.00 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
CAPLIN POINT LABORATORIES LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
2,187 crNet profit (TTM)
650 crEBIT (TTM)
804 crProfit before tax (TTM)
803 crNet margin (TTM)
29.7%Finance costs (TTM)
0.9 crBalance sheet, as filed 2026-03-31
Total assets
4,045 crShareholder equity
3,631 crTotal borrowings
0.6 crCash and equivalents
94.2 crInventory
429 crTrade receivables
826 crThe cash engine, latest filed year
Operating cash flow
523 crCapex
248 crFree cash flow
275 crInvesting flow
-582 crFinancing flow
-46.5 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 2,187 cr | 650 cr | 3,631 cr | 0.6 cr | 523 cr |
| FY25 | 1,937 cr | 541 cr | 2,886 cr | 0.6 cr | 432 cr |
| FY24 | 1,694 cr | 461 cr | 2,347 cr | 1.2 cr | 311 cr |
| FY23 | 1,467 cr | 377 cr | 1,907 cr | 3.4 cr | 272 cr |
| FY22 | 1,269 cr | 308 cr | 1,510 cr | 0.5 cr | 337 cr |
| FY21 | 1,061 cr | 251 cr | 1,203 cr | 17.1 cr | n/a |
Every figure is parsed from CAPLIN POINT LABORATORIES LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
What changed24 disclosures
Every recent official filing from CAPLIN POINT LABORATORIES LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
CAPLIN POINT LABORATORIES LIMITED has filed 24 official disclosures recently. The most recent is a Regulatory dated 11 Jul 2026.
Event Heat
52 / 100Certificate under SEBI (Depositories and Participants) Regulations, 2018
the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Caplin Point Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Event Heat is a dated net read of CAPLIN POINT LABORATORIES LIMITED's last 90 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the CAPLIPOINT chart. Not a substitute for a registered research note.
| Ticker | CAPLIPOINT |
|---|---|
| Full name | CAPLIN POINT LABORATORIES LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE475E01026 |
| Market-cap band | ~20,146 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | CAPLIPOINT |
Reference chartLevels in show
The daily frame the desk reads on CAPLIPOINT.
FAQ12 reader questions · AEO-eligible
The line on CAPLIPOINT, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the CAPLIPOINT share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on CAPLIPOINT. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for CAPLIPOINT?
The BazaarBaazi Crack Score for CAPLIPOINT is 98 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on CAPLIPOINT?
Strike-level option inventory for CAPLIPOINT is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is CAPLIPOINT in and which peers does BazaarBaazi track?
CAPLIPOINT sits in Healthcare (mid cap), indicative market cap ~20,146 cr (indicative), ISIN INE475E01026. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on CAPLIN POINT LABORATORIES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the CAPLIPOINT view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on CAPLIPOINT is bullish, published in Systematic Read on 21 Jul 2026.
Is CAPLIPOINT a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, CAPLIN POINT LABORATORIES LIMITED sits in the Near-perfect tier with a setup score of 95/100 (technical 100, fundamental 100). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
What was CAPLIN POINT LABORATORIES LIMITED's Q4 FY26 net profit?
CAPLIN POINT LABORATORIES LIMITED reported a net profit of Rs 173 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +19.0% year on year. The figure is from the company's official NSE filing.
What was CAPLIN POINT LABORATORIES LIMITED's Q4 FY26 revenue?
CAPLIN POINT LABORATORIES LIMITED reported revenue of Rs 600 cr for Q4 FY26. That is +19.4% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate CAPLIN POINT LABORATORIES LIMITED's Q4 FY26 result?
BazaarBaazi gives CAPLIN POINT LABORATORIES LIMITED's Q4 FY26 result a Result Pulse of 85 out of 100, with a verdict of Profit acceleration. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Caplin Point Laboratories Ltd announced recently?
Caplin Point Laboratories Ltd's two most material recent disclosures are a regulatory dated 11 Jul 2026, "Certificate under SEBI (Depositories and Participants)…", and an insider trade dated 27 Jun 2026, "the Trading Window closure pursuant to SEBI (Prohibition…". Both link to the company's own official filing on the BazaarBaazi stock page.
Has Caplin Point Laboratories Ltd declared a dividend recently?
Yes. Caplin Point Laboratories Ltd filed a dividend disclosure on 29 May 2026, filed as "Interim Dividend - Rs 4 Per Share". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.
What did Caplin Point Laboratories Ltd's latest board meeting cover?
Caplin Point Laboratories Ltd's most recent board-meeting disclosure on record dated 14 May 2026 reads "Board Meeting to be held on 14-May-2026 to consider and approve the…". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.
Related stock views
The names BazaarBaazi reads alongside CAPLIPOINT, each a living view refreshed every end-of-day run.